BRAIN Biotech (BNN.DE) Osake Kurssi

BRAIN Biotechnology Research and Information Network AG is primarily active in the biotechnology industry.

The main competitors of BRAIN Biotechnology Research and Information Network AG in the market include companies such as BASF SE, Novozymes A/S, and Codexis, Inc. These companies are also involved in the biotechnology and research sectors, offering innovative solutions and products. However, BRAIN AG differentiates itself through its comprehensive portfolio of bio-based products, cutting-edge technologies, and expertise in biotechnology, strand synthesis, and enzyme engineering. This allows BRAIN AG to offer customized and sustainable solutions for various industries, including food and nutrition, pharmaceuticals, and cosmetics.

BRAIN Biotechnology Research and Information Network AG, commonly known as BRAIN AG, is a renowned company in the biotechnology sector. Established in 1993, BRAIN AG has a strong history of pioneering advancements in the field of industrial biotechnology. This German-based company specializes in the discovery and development of innovative bio-based products and solutions. With a focus on exploiting the vast potential of nature's biodiversity, BRAIN AG applies its unique BioArchive to identify novel enzymes, microorganisms, and natural substances for various industrial applications. Over the years, BRAIN AG has successfully collaborated with numerous industry partners, leading to groundbreaking innovations in areas such as agriculture, consumer goods, and pharmaceuticals. With its rich history and expertise, BRAIN AG continues to redefine the boundaries of biotechnological research and development.

BRAIN Biotechnology Research and Information Network AG has achieved several significant milestones since its inception. The company has successfully established itself as a leading provider of innovative solutions in the field of biotechnology research and information. BRAIN AG has developed groundbreaking technologies and solutions that have revolutionized many industries, including pharmaceuticals, agriculture, and nutrition. The company's collaborative efforts with renowned partners have resulted in numerous successful research projects and product developments. Additionally, BRAIN AG has received prestigious recognition and awards for its outstanding contributions to the biotechnology sector. Overall, BRAIN Biotechnology Research and Information Network AG continues to make remarkable strides in advancing the boundaries of biotechnology innovation and research.

BRAIN Biotechnology Research and Information Network AG primarily operates in Germany and has a strong presence in Europe.

BRAIN Biotechnology Research and Information Network AG represents core values of innovation, collaboration, and sustainable development in the biotechnology research and information sector. With a steadfast commitment to utilizing cutting-edge technology, BRAIN AG strives to revolutionize industries by harnessing the power of nature's vast biodiversity. By fostering strong partnerships and collaborations, BRAIN AG aims to provide novel solutions that address challenges in areas such as healthcare, nutrition, and consumer goods. With a focus on sustainability, BRAIN AG actively promotes environmentally friendly practices and the responsible use of resources. BRAIN AG's corporate philosophy revolves around unlocking the potential of nature and delivering value to its stakeholders through pioneering biotechnological research and information networks.

Analyytikot asettavat tällä hetkellä BRAIN Biotech-osakkeelle keskimääräisen tavoitehinnan 5,34 EUR (mediaani: 5,10 EUR), mikä merkitsee +92,3 % viimeisimpään hintaan verrattuna. Konsensus perustuu 9 analyytikkoarvioon.

BRAIN Biotech Analyytikkojen kursstavoitteet 2026

9 analyytikkoa arvioi tällä hetkellä BRAIN Biotech-osaketta: 8 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat BRAIN Biotech-yhtiöltä 48,18 M EUR liikevaihtoa ja −0,54 EUR osakekohtaista tulosta.

BRAIN Biotech Analyytikkojen kursstavoitteet 2026

BRAIN Biotech-osake (BNN.DE) on listattuna 7 pörssissä, muun muassa: London (0RFI.L), SIX (Zürich) (BNN.SW), XETRA (BNN.DE), Frankfurt (BNN.F), München (BNN.MU), Düsseldorf (BNN.DU), Hamburg (BNN.HM).

The BRAIN Biotechnology Research and Information Network AG specializes in the research and development of innovative biotechnological products. The company is divided into three different divisions: BioScience, BioIndustrial, and BioResources. The BioScience division focuses primarily on identifying and characterizing new active substances and enzymes from nature. BRAIN works closely with various global industrial companies to translate research findings into marketable products. The BioScience division is also responsible for conducting customized research projects tailored to the specific needs of the companies. BRAIN's BioIndustrial division focuses on the development and production of customized enzymes and microorganisms for industrial applications in various industries, such as food, paper, and textile. By using biotechnological processes, products can be produced in a more environmentally friendly manner and resources can be saved. BRAIN's BioResources division specializes in the use of biomass for the extraction of valuable raw materials. Sustainable and environmentally friendly methods are used to produce high-quality products such as bioenergy, biorefinery products, and biopolymers from biological waste and residues. BRAIN offers customers a comprehensive range of services in the field of biotechnological research and development. The company emphasizes a strong customer-oriented approach and close collaboration with industry partners. BRAIN has a large number of patents and market approvals that emphasize the high quality of its products. BRAIN's products include enzymes for the food industry for cheese and bread production, as well as specially adapted microorganisms for the production of bioethanol or biogas. In the cosmetics industry, BRAIN also offers innovative solutions such as natural active ingredients for skin and hair care products. In summary, BRAIN offers a wide range of biotechnological solutions for sustainable and efficient production in various industries. The close collaboration with industry partners allows for meeting individual customer needs and offering tailored solutions. BRAIN is an innovative company that is globally at the forefront of biotechnology due to its high level of research and development performance and the use of state-of-the-art technology. BRAIN specializes in the research and development of biotechnological products in various industries.

odotettu liikevaihto BRAIN Biotech on 48,18 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto BRAIN Biotech on −11,69 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

BRAIN Biotech:n hinta-voitto-suhde (P/E) on tällä hetkellä −5,19. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan BRAIN Biotech-osakkeen arvostusta.

BRAIN Biotech:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,26. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii BRAIN Biotech-osakkeen arvostuskennuslukuna.

BRAIN Biotech:n Eulpool-laatuscore on 4/10.

BRAIN Biotech:n ISIN on DE0005203947. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

BRAIN Biotech:n WKN on 520394. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

BRAIN Biotech:n ticker on BNN.DE. Tämä pörssinoteeraus käytetään BRAIN Biotech-osakkeiden kauppaan pörssissä.